CN108904469B - 一种dqa包载介孔二氧化硅载小分子药物靶向线粒体的载体的制备方法 - Google Patents
一种dqa包载介孔二氧化硅载小分子药物靶向线粒体的载体的制备方法 Download PDFInfo
- Publication number
- CN108904469B CN108904469B CN201810745757.1A CN201810745757A CN108904469B CN 108904469 B CN108904469 B CN 108904469B CN 201810745757 A CN201810745757 A CN 201810745757A CN 108904469 B CN108904469 B CN 108904469B
- Authority
- CN
- China
- Prior art keywords
- dqa
- mesoporous silica
- medicine
- carrier
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 8
- 230000008685 targeting Effects 0.000 title claims description 9
- 229940126586 small molecule drug Drugs 0.000 title claims description 7
- 239000003814 drug Substances 0.000 claims abstract description 38
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000002105 nanoparticle Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000001953 recrystallisation Methods 0.000 claims abstract description 8
- 239000011148 porous material Substances 0.000 claims abstract description 7
- 238000011068 loading method Methods 0.000 claims abstract description 6
- 239000000523 sample Substances 0.000 claims abstract description 6
- 229960001378 dequalinium chloride Drugs 0.000 claims description 34
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 claims description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadec-1-ene Chemical compound CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 238000002604 ultrasonography Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 7
- 229940109262 curcumin Drugs 0.000 claims description 6
- 235000012754 curcumin Nutrition 0.000 claims description 6
- 239000004148 curcumin Substances 0.000 claims description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000003760 magnetic stirring Methods 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000009489 vacuum treatment Methods 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 4
- 238000006703 hydration reaction Methods 0.000 claims description 4
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 claims description 4
- 229940009456 adriamycin Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 6
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000000089 atomic force micrograph Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000013335 mesoporous material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen radicals Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810745757.1A CN108904469B (zh) | 2018-07-09 | 2018-07-09 | 一种dqa包载介孔二氧化硅载小分子药物靶向线粒体的载体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810745757.1A CN108904469B (zh) | 2018-07-09 | 2018-07-09 | 一种dqa包载介孔二氧化硅载小分子药物靶向线粒体的载体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108904469A CN108904469A (zh) | 2018-11-30 |
CN108904469B true CN108904469B (zh) | 2021-05-14 |
Family
ID=64425668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810745757.1A Active CN108904469B (zh) | 2018-07-09 | 2018-07-09 | 一种dqa包载介孔二氧化硅载小分子药物靶向线粒体的载体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108904469B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529504B (zh) * | 2020-03-25 | 2023-01-10 | 西安组织工程与再生医学研究所 | 功能性嵌合凋亡小体及其制备方法和应用 |
CN111529505B (zh) * | 2020-03-25 | 2023-04-11 | 西安组织工程与再生医学研究所 | 功能性嵌合凋亡小体及其制备方法和应用 |
CN111588704B (zh) * | 2020-07-01 | 2023-04-11 | 西安组织工程与再生医学研究所 | 靶向响应性释放系统及其制备方法和应用 |
CN113229275B (zh) * | 2021-05-28 | 2022-05-24 | 河南农业大学 | 一种介孔二氧化硅颗粒农药载体及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013096A1 (en) * | 1997-09-08 | 1999-03-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
CN102757555A (zh) * | 2011-04-29 | 2012-10-31 | 北京大学 | 地喹氯铵-聚乙二醇-二硬脂酰磷脂酰乙醇胺共轭化合物及其修饰的白藜芦醇脂质体 |
-
2018
- 2018-07-09 CN CN201810745757.1A patent/CN108904469B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013096A1 (en) * | 1997-09-08 | 1999-03-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
CN102757555A (zh) * | 2011-04-29 | 2012-10-31 | 北京大学 | 地喹氯铵-聚乙二醇-二硬脂酰磷脂酰乙醇胺共轭化合物及其修饰的白藜芦醇脂质体 |
Non-Patent Citations (2)
Title |
---|
Biphase Stratification Approach to Three-Dimensional Dendritic Biodegradable Mesoporous Silica Nanospheres;Shen, et al;《Nano letters》;20140212;第14卷(第2期);923-932 * |
Design and Development of Novel Mitochondrial Targeted Nanocarriers, DQAsomes for Curcumin Inhalation;Spela Zupancic,et al;《Molecular Pharmaceutics》;20140707;第11卷(第7期);2334-2345 * |
Also Published As
Publication number | Publication date |
---|---|
CN108904469A (zh) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108904469B (zh) | 一种dqa包载介孔二氧化硅载小分子药物靶向线粒体的载体的制备方法 | |
Kumar et al. | Preparation of luliconazole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity | |
Velmurugan et al. | Development and optimization of ifosfamide nanostructured lipid carriers for oral delivery using response surface methodology | |
Zhang et al. | Synthesis of nanogels via cell membrane-templated polymerization | |
Upadhyaya et al. | Efficient water soluble nanostructured ZnO grafted O-carboxymethyl chitosan/curcumin-nanocomposite for cancer therapy | |
Upadhyaya et al. | In situ grafted nanostructured ZnO/carboxymethyl cellulose nanocomposites for efficient delivery of curcumin to cancer | |
Patel et al. | Effect of penetration enhancers and amorphization on transdermal permeation flux of raloxifene-encapsulated solid lipid nanoparticles: an ex vivo study on human skin | |
Lee et al. | Size control of self-assembled nanoparticles by an emulsion/solvent evaporation method | |
Du et al. | Alginate‐based microcapsules with a molecule recognition linker and photosensitizer for the combined cancer treatment | |
Guo et al. | Synthesis and antitumoral activity of gelatin/polyoxometalate hybrid nanoparticles | |
Guo et al. | Nanoscale hybrid coating enables multifunctional tissue scaffold for potential multimodal therapeutic applications | |
Eid et al. | Sustained broad-spectrum antibacterial effects of nanoliposomes loaded with silver nanoparticles | |
CN106177982A (zh) | 一种透明质酸修饰的脂质介孔硅核壳纳米组装体及其制备方法 | |
Li et al. | RETRACTED: Pluronic® F127 stabilized reduced graphene oxide hydrogel for transdermal delivery of ondansetron: Ex vivo and animal studies | |
Ensafi et al. | Study the role of poly (diethyl aminoethyl methacrylate) as a modified and grafted shell for TiO2 and ZnO nanoparticles, application in flutamide delivery | |
Tao et al. | Minimally invasive antitumor therapy using biodegradable nanocomposite micellar hydrogel with functionalities of Nir-II photothermal ablation and vascular disruption | |
Lewandowska-Łańcucka et al. | Silicone-stabilized liposomes as a possible novel nanostructural drug carrier | |
Wu et al. | Elaboration and characterization of curcumin-loaded Tri-CL-mPEG three-arm copolymeric nanoparticles by a microchannel technology | |
Yao et al. | Azobenzene-based cross-linked small-molecule vesicles for precise oxidative damage treatments featuring controlled and prompt molecular release | |
CN108478521A (zh) | 一种载有脂质体顺铂纳米颗粒的可溶解微针及其制备方法 | |
Kou et al. | Preparation and application of a polymer with pH/temperature-responsive targeting | |
Subbiah et al. | Deformable nanovesicles synthesized through an adaptable microfluidic platform for enhanced localized transdermal drug delivery | |
Ge et al. | Walnut kernel-like mesoporous silica nanoparticles as effective drug carrier for cancer therapy in vitro | |
CN103520112A (zh) | 小粒径纳米颗粒的制备方法及纳米颗粒药物载体 | |
CN100479806C (zh) | 一种具有高效抗肿瘤活性的纳米结构脂质载体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220207 Address after: 510098 room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong Patentee after: Guangzhou Zhikun Biotechnology Co.,Ltd. Address before: 510640 No. five, 381 mountain road, Guangzhou, Guangdong, Tianhe District Patentee before: SOUTH CHINA University OF TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231213 Address after: Room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong, 510030 Patentee after: Guangzhou Zhiyuan Biotechnology Co.,Ltd. Address before: 510098 room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong Patentee before: Guangzhou Zhikun Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |